BackTable

Podcast #177 · 9 Jul 2024

Latest Approaches to Treat High-Risk NMIBC

Dr. Ashish Kamat discusses contemporary management of high-risk, non-muscle-invasive bladder cancer (NMIBC) and his thoughts into the future of this arena.

This podcast is supported by

Siemens Healthineers Theranostics

Timestamps

Resources

You may also like

Loading
Loading
Loading
Loading

More about this episode

Dr. Kamat explores the evolving role of BCG and potential alternative therapies such as gemcitabine and docetaxel. He also covers effective clinical management, emerging clinical trials, and nuanced decision-making principles for radical cystectomy. Finally, the conversation touches on Dr. Kamat’s expert insights regarding the future of NMIBC management, including predictive biomarkers and personalized medicine.